ZymoGenetics

ZymoGenetics has proteins on its plate. The firm culls genomics databases to indentify and develop protein-based drugs targeting a variety conditions. Its sole commercial product, RECOTHROM (rThrombin), controls bleeding during surgery. Unlike existing forms of thrombin, RECOTHROM is derived from recombinant proteins instead of animal or human blood, which can trigger adverse reactions. The lead candidate in ZymoGenetics' research and development pipeline is an antiviral therapy to treat hepatitis C. The company is a wholly owned subsidiary of Bristol-Myers Squibb (BMS).